- Home
- KURA vs PSNL Comparison
KURA vs PSNL Comparison
Compare KURA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.13
HOLD
Current Price
$9.32
Company Overview
Basic Information| Metric | KURA | PSNL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.1M | 746.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | KURA | PSNL |
|---|---|---|
| Price | $8.13 | $9.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $26.88 | $11.17 |
| AVG Volume (30 Days) | ★ 1.4M | 1.4M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,029,000.00 | $69,103,000.00 |
| Revenue This Year | $88.72 | N/A |
| Revenue Next Year | $76.50 | $19.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.41 | $2.83 |
| 52 Week High | $12.49 | $11.50 |
Technical Indicators
Market Signals| Indicator | KURA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 49.42 |
| Support Level | $8.02 | $9.01 |
| Resistance Level | $9.18 | $10.69 |
| Average True Range (ATR) | 0.41 | 0.84 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 13.48 | 40.22 |
Price Performance
Historical Comparison KURA
PSNL
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.